Products > Respiratory Infections
The most successful treatment at present is the aerosolised (inhaled) form of the antibiotic Tobramycin, which is used by approximately a fifth of the 70,000 to 80,000 cystic fibrosis sufferers in the major pharmaceutical markets worldwide. The annual cost associated with such a treatment, however, is approximately US $20,000/patient. Mucus-targeting (DNAses) and mucoactive agents (polyols) have a lower risk of resistance development than current antibiotic therapies and are predicted to represent more than a third of a nearly US $2 billion-worth estimated market by 2015.
NovaBiotics' novel antimicrobial peptides have a lower risk of resistance development than currently used antibiotics, can also be aerosolised to facilitate delivery directly to the target sites within the lung, and show synergistic effects with mucolytic agents in in vitro bacterial biofilm models. Uniquely, NovaBiotics’ synergistic therapeutic compounds demonstrate antimicrobial activity against planktonic, biofilm and persister bacterial cells, which are the main cause of recurring respiratory infections.
NovaBiotics Ltd is targeting the life-threatening community and hospital acquired lung infections that are caused by the Gram negative bacterium Pseudomonas aeruginosa (P. aeruginosa). P. aeruginosa also exacerbates the progressive lung damage associated with Cystic Fibrosis (CF), colonising the lungs of most Cystic Fibrosis sufferers by 10 years of age and thereafter potentially leading to chronic infection and progressive deterioration in lung function; the main cause of mortality for CF patients.
P. aeruginosa is therefore a major target for NovaBiotics and the Company has unique technology that has the potential to succeed where conventional therapies for respiratory and Cystic Fibrosis-associated infections have failed. NovaBiotics' novel technology is not sensitive to the ionic environment of the mucosal epithelial tissues of Cystic Fibrosis sufferers, a factor that has impinged on the success of other similar experimental antimicrobial therapies.
NovaBiotics Ltd is targeting the life-threatening community and hospital acquired lung infections that are caused by the Gram negative bacterium Pseudomonas aeruginosa (P. aeruginosa). P. aeruginosa also exacerbates the progressive lung damage associated with Cystic Fibrosis (CF), colonising the lungs of most Cystic Fibrosis sufferers by 10 years of age and thereafter potentially leading to chronic infection and progressive deterioration in lung function; the main cause of mortality for CF patients.
P. aeruginosa is therefore a major target for NovaBiotics and the Company has unique technology that has the potential to succeed where conventional therapies for respiratory and Cystic Fibrosis-associated infections have failed. NovaBiotics' novel technology is not sensitive to the ionic environment of the mucosal epithelial tissues of Cystic Fibrosis sufferers, a factor that has impinged on the success of other similar experimental antimicrobial therapies.
Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK
© NovaBiotics Ltd 2009.
All Rights Reserved
Last updated
8 February, 2010
